Patent US1922713A successfully refreshed from Google Patents.
Patent US2870571A successfully refreshed from Google Patents.
Patent US2488199A successfully refreshed from Google Patents.
Patent US7234951B2 successfully refreshed from Google Patents.
Patent US5622856A successfully refreshed from Google Patents.
US5622856A
Expired / Lapsed
US
⏱️ 0.0 years remaining
High efficiency helper system for AAV vector production
Assignee: Genzyme Corp
•
Filing: 1995-08-03
•
Granted: 1997-04-22
•
Expires: 2015-08-03
Abstract
Abstract Novel nucleic acid molecules are provided having adeno-associated virus (AAV) coding regions that are capable of expressing necessary AAV functions to complement an AAV vector in the production of recombinant AAV (rAAV) virions. The molecules feature a nucleotide sequence that is substantially homologous to an AAV p5 promoter region, wherein the p5 promoter region is situated in the molecules in a site that is other than its natural position relative to the AAV rep coding region in the wild-type AAV genome. AAV helper function constructs are also provided, comprising the instant nucleic acid molecules embodied in a replicon that is capable of being transcribed and translated to express complementing AAV helper functions in a suitable host cell. Novel AAV packaging cells and AAV producer cells are provided, which contain the AAV helper constructs of the invention, and methods of producing enhanced levels of rAAV virions using the AAV helper constructs of the invention are also provided. Methods are also provided for producing rAAV virions without the concomitant production of significant levels of wild-type AAV.
Inventors
- 👤 Georges Natsoulis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 12:04
CPC Classifications
C; C12; C12N; C12N7/00; C07; C07K; C07K14/00; C07K14/005; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; C07K2319/00; C12N2750/00; C12N2750/00011; C12N2750/14011; C12N2750/14111; C12N2750/14122; C12N2750/14141; C12N2750/14143; C12N2750/14151; C12N2750/14152; C12N2750/14161; C12N2750/14162; C12N2800/00; C12N2800/30
Claims Analysis
Total Claims: 36
Claim 1
Independent Claim
55 words
A nucleic acid molecule encoding AAV helper functions, said molecule comprising: an AAV rep coding region; an AAV cap coding region; and a first nucleotide sequence comprising an AAV p5 promoter region, said first nucleotide sequence arranged in the molecule such that the p5 promoter region is situated 3' relative to the rep coding region.
Claim 2
Dependent Claim
55 words
A nucleic acid molecule encoding AAV helper functions, said molecule comprising: an AAV rep coding region; an AAV cap coding region; and a first nucleotide sequence comprising an AAV p5 promoter region, said first nucleotide sequence arranged in the molecule such that the p5 promoter region is situated 3' relative to the rep coding region.
Claim 3
Dependent Claim
38 words
The nucleic acid molecule of claim 1, wherein the first nucleotide sequence comprises base pairs (bps) 145 through 309 as depicted in FIG. 4 (SEQ ID NO:4) of the wild-type AAV serotype 2 genome, or functional equivalents thereof.
Claim 4
Dependent Claim
36 words
The nucleic acid molecule of claim 1, wherein the first nucleotide sequence comprises bps 145 through 494 as depicted in FIG. 4 (SEQ ID NO:4) of the wild-type AAV serotype 2 genome, or functional equivalents thereof.
Claim 5
Dependent Claim
69 words
The nucleic acid molecule of claim 1, further including a second nucleotide sequence comprising a Flip Recombination Target (FRT) site or a functional equivalent thereof, said second nucleotide sequence positioned such that the molecule comprises, in the order given in the 5' to 3' direction, the second nucleotide sequence, an AAV rep coding region, an AAV cap coding region, and a nucleotide sequence comprising an AAV p5 promoter region.
Claim 6
Dependent Claim
61 words
The nucleic acid molecule of claim 1, further comprising a 5' and a 3' flanking nucleotide sequence, wherein each said flanking sequence comprises an FRT site or a functional equivalent thereof, and further wherein the AAV rep coding region, the AAV cap coding region, and the nucleotide sequence comprising the AAV p5 promoter region are interposed between said flanking nucleotide sequences.
Claim 7
Dependent Claim
51 words
The nucleic acid molecule of claim 1, further comprising an intervening nucleotide sequence, wherein the molecule comprises, in the order given in the 5' to 3' direction, an AAV rep coding region, an AAV cap coding region, the intervening nucleotide sequence, and a nucleotide sequence comprising an AAV p5 promoter region.
Claim 8
Dependent Claim
12 words
An AAV helper construct comprising the nucleic acid molecule of claim 1.
Claim 9
Dependent Claim
66 words
The nucleic acid molecule of claim 3, further including a second nucleotide sequence comprising an FRT site or a functional equivalent thereof, said second nucleotide sequence positioned such that the molecule comprises, in the order given in the 5' to 3' direction, the second nucleotide sequence, an AAV rep coding region, an AAV cap coding region, and a nucleotide sequence comprising an AAV p5 promoter region.
Claim 10
Dependent Claim
61 words
The nucleic acid molecule of claim 3, further comprising a 5' and a 3' flanking nucleotide sequence, wherein each said flanking sequence comprises an FRT site or a functional equivalent thereof, and further wherein the AAV rep coding region, the AAV cap coding region, and the nucleotide sequence comprising the AAV p5 promoter region are interposed between said flanking nucleotide sequences.
Claim 11
Dependent Claim
40 words
The nucleic acid molecule of claim 3, wherein the nucleotide sequence that comprises the AAV p5 promoter region further comprises an FRT site inserted therein such that said FRT site is situated immediately 3' of the AAV p5 promoter region.
Claim 12
Dependent Claim
74 words
The nucleic acid molecule of claim 10, further including a second nucleotide sequence comprising an FRT site or a functional equivalent thereof, wherein the molecule comprises, in the order given in the 5' to 3' direction, the second nucleotide sequence, an AAV rep coding region, an AAV cap coding region, and a nucleotide sequence comprising an AAV p5 promoter region and having an FRT site situated immediately 3' of the AAV p5 promoter region.
Claim 13
Dependent Claim
12 words
An AAV helper construct comprising the nucleic acid molecule of claim 11.
Claim 14
Dependent Claim
44 words
The nucleic acid molecule of claim 6, wherein the intervening nucleotide sequence has a length sufficient to prevent the packaging in an AAV virion of a molecule produced by a recombination of said nucleic acid molecule with AAV ITRs during recombinant AAV virion production.
Claim 15
Dependent Claim
12 words
An AAV helper construct comprising the nucleic acid molecule of claim 13.
Claim 16
Dependent Claim
13 words
The AAV helper construct of claim 7, wherein said construct comprises a plasmid.
Claim 17
Dependent Claim
11 words
The construct of claim 7, further comprising a selectable genetic marker.
Claim 18
Dependent Claim
19 words
An AAV packaging cell prepared by transfecting a suitable host cell with the AAV helper construct of claim 7.
Claim 19
Dependent Claim
62 words
A method of producing recombinant AAV virions, comprising the steps: (a) introducing an AAV vector into a host cell; (b) introducing the AAV helper construct of claim 7 into the host cell such that the construct provides essential AAV Rep and Cap polypeptides; (c) expressing viral helper functions in the host cell; and (d) culturing the cell to produce recombinant AAV virions.
Claim 20
Dependent Claim
13 words
The AAV helper construct of claim 12, wherein said construct comprises a plasmid.
Claim 21
Dependent Claim
18 words
The AAV helper construct of claim 19, wherein said construct comprises the plasmid pGN1909 (ATCC Accession Number 69871).
Claim 22
Dependent Claim
11 words
The construct of claim 20, further comprising a selectable genetic marker.
Claim 23
Dependent Claim
19 words
An AAV packaging cell prepared by transfecting a suitable host cell with the AAV helper construct of claim 20.
Claim 24
Dependent Claim
62 words
A method of producing recombinant AAV virions, comprising the steps: (a) introducing an AAV vector into a host cell; (b) introducing the AAV helper construct of claim 20 into the host cell such that the construct provides essential AAV Rep and Cap polypeptides; (c) expressing viral helper functions in the host cell; and (d) culturing the cell to produce recombinant AAV virions.
Claim 25
Dependent Claim
13 words
The AAV helper construct of claim 14, wherein said construct comprises a plasmid.
Claim 26
Dependent Claim
11 words
The construct of claim 14, further comprising a selectable genetic marker.
Claim 27
Dependent Claim
19 words
An AAV packaging cell prepared by transfecting a suitable host cell with the AAV helper construct of claim 14.
Claim 28
Dependent Claim
62 words
A method of producing recombinant AAV virions, comprising the steps: (a) introducing an AAV vector into a host cell; (b) introducing the AAV helper construct of claim 14 into the host cell such that the construct provides essential AAV Rep and Cap polypeptides; (c) expressing viral helper functions in the host cell; and (d) culturing the cell to produce recombinant AAV virions.
Claim 29
Dependent Claim
15 words
The construct of claim 16, wherein the selectable genetic marker comprises an antibiotic resistance gene.
Claim 30
Dependent Claim
15 words
The construct of claim 21, wherein the selectable genetic marker comprises an antibiotic resistance gene.
Claim 31
Dependent Claim
15 words
The construct of claim 25, wherein the selectable genetic marker comprises an antibiotic resistance gene.
Claim 32
Dependent Claim
35 words
An AAV producer cell capable of producing recombinant AAV virions when viral helper functions are expressed therein, said producer cell comprising the packaging cell of claim 22 that has been transfected with an AAV vector.
Claim 33
Dependent Claim
35 words
An AAV producer cell capable of producing recombinant AAV virions when viral helper functions are expressed therein, said producer cell comprising the packaging cell of claim 26 that hag been transfected with an AAV vector.
Claim 34
Dependent Claim
33 words
The method of claim 18, wherein the expression of viral helper functions is provided by infecting the host cell with a virus selected from the group consisting of adenovirus, herpesvirus and vaccinia virus.
Claim 35
Dependent Claim
33 words
The method of claim 23, wherein the expression of viral helper functions is provided by infecting the host cell with a virus selected from the group consisting of adenovirus, herpesvirus and vaccinia virus.
Claim 36
Dependent Claim
33 words
The method of claim 27, wherein the expression of viral helper functions is provided by infecting the host cell with a virus selected from the group consisting of adenovirus, herpesvirus and vaccinia virus.
References Cited (Backward Citations)
US5139941A
Cited
US5436146A
Cited
US5173414A
Cited
WO1995006743A2
Cited
WO1995013392A1
Cited
WO1995013365A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-04-21 | 2000-10-21 | 2001-04-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-04-21 | 2004-10-21 | 2005-04-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-04-21 | 2008-10-21 | 2009-04-22 | $7700.00 | Window Closed / Lapsed |